GlaxoSmithKline (GSK) Offers Statement in Response to New York Times Article on China

November 2, 2016 1:58 PM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

GlaxoSmithKline (NYSE: GSK) said on its website:

These matters relating to our operations in China were deeply disappointing to GSK. They have previously been the subject of investigation by authorities in China and the United States. GSK cooperated fully with those investigations, which have since concluded and been resolved. GSK is committed to operating its commercial activities in an ethical and professional manner consistent with the Company’s values. Over the last few years, GSK has made significant changes to its commercial practices globally, which include changes to the way the Company’s sales representatives are compensated and stopping payments to Healthcare Practitioners to speak to other providers about its products.

More information on our business model changes is available here:

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments

Add Your Comment